keyword
MENU ▼
Read by QxMD icon Read
search

prognostic biomarker bladder

keyword
https://www.readbyqxmd.com/read/29682192/-atm-rb1-mutations-predict-shorter-overall-survival-in-urothelial-cancer
#1
Ming Yin, Petros Grivas, Hamid Emamekhoo, Prateek Mendiratta, Siraj Ali, JoAnn Hsu, Monali Vasekar, Joseph J Drabick, Sumanta Pal, Monika Joshi
Background: Mutations of DNA repair genes, e.g. ATM/RB1 , are frequently found in urothelial cancer (UC) and have been associated with better response to cisplatin-based chemotherapy. Further external validation of the prognostic value of ATM/RB1 mutations in UC can inform clinical decision making and trial designs. Results: In the discovery dataset, ATM/RB1 mutations were present in 24% of patients and were associated with shorter OS (adjusted HR 2.67, 95% CI, 1...
March 30, 2018: Oncotarget
https://www.readbyqxmd.com/read/29662611/gpx2-promotes-development-of-bladder-cancer-with-squamous-cell-differentiation-through-the-control-of-apoptosis
#2
Taku Naiki, Aya Naiki-Ito, Keitaro Iida, Toshiki Etani, Hiroyuki Kato, Shugo Suzuki, Yoriko Yamashita, Noriyasu Kawai, Takahiro Yasui, Satoru Takahashi
Herein, we elucidated the molecular mechanisms and therapeutic potential of glutathione peroxidase 2 (GPX2) in bladder cancer. GPX2 expression gradually increased during progression from normal to papillary or nodular hyperplasia (PNHP) and urothelial carcinoma (UC) in a rat N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced bladder carcinogenesis model. GPX2 overexpression was more marked in UC with squamous differentiation (SqD) than in pure UC. Clinical intraepithelial lesions of papillary UC and invasive UC with SqD also had strong GPX2 expression in human radical cystectomy specimens...
March 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29644173/identification-of-hypoxic-gene-signature-as-a-prognostic-and-predictive-biomarker-to-determine-effective-therapy-in-high-risk-bladder-cancer-patients
#3
EDITORIAL
Zheng Tan, Ninadh M D'Costa, Peter A Raven, Claudia Chavez-Munoz, Alan I So
No abstract text is available yet for this article.
March 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/29620229/mir%C3%A2-22%C3%A2-3p-enhances-multi%C3%A2-chemoresistance-by-targeting-net1-in-bladder-cancer-cells
#4
Jun Xiao, Sanqiang Niu, Jiahong Zhu, Lei Lv, Hui Deng, Daqing Pan, Deyun Shen, Congyun Xu, Zhou Shen, Tao Tao
With the discovery of new chemotherapeutic drugs, chemotherapy becomes increasingly valuable. However, the resistance of tumor cells to chemotherapeutic agents significantly limits the effectiveness and causes chemotherapy failure. MicroRNAs have been shown to regulate drug resistance in many types of cancer. In the present study, we measured the chemosensitivity of five bladder cancer (BCa) cell lines to seven commonly used chemotherapeutic drugs by Vita‑Blue assay. We then identified the most sensitive (5637) and most tolerant cell lines (H‑bc) and conducted a multi‑group test...
April 4, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29605462/high-expression-of-long-noncoding-rna-norad-indicates-a-poor-prognosis-and-promotes-clinical-progression-and-metastasis-in-bladder-cancer
#5
Qiaqia Li, Chao Li, Jinbo Chen, Peihua Liu, Yu Cui, Xinyi Zhou, Huihuang Li, Xiongbing Zu
PURPOSE: To explore the function of NORAD in bladder cancer (BC), and to verify whether NORAD could be used as a biomarker to determine preoperative presence of progression and lymph node metastasis. To our knowledge, it is the first study investigating NORAD and its implications in BC. METHODS: BC specimens of 90 patients underwent bladder cystectomy or transurethral resection between January 2012 to December 2016 were tested by fluorescence in situ hybridization...
March 28, 2018: Urologic Oncology
https://www.readbyqxmd.com/read/29587848/cytokeratin-5-6-expression-in-bladder-cancer-association-with-clinicopathologic-parameters-and-prognosis
#6
Atif Ali Hashmi, Zubaida Fida Hussain, Muhammad Irfan, Muhammad Muzzammil Edhi, Sarah Kanwal, Naveen Faridi, Amir Khan
OBJECTIVES: Well differentiated keratinized squamous component as a part of urothelial carcinoma can be easily appreciated; however non-keratinizing squamous differentiation closely resembles urothelial differentiation. In addition prognostic significance of CK 5/6 expression in the absence of apparent squamous differentiation is still unclear. Therefore, in the present study we aimed to evaluate the frequency of CK 5/6 expression in 127 cases of urothelial carcinoma and its prognostic significance in loco-regional population...
March 27, 2018: BMC Research Notes
https://www.readbyqxmd.com/read/29577645/a-novel-monoclonal-antibody-kmp1-has-potential-antitumor-activity-of-bladder-cancer-by-blocking-cd44-in-vivo-and-in-vitro
#7
Yujin Chen, Haifeng Wang, Yigang Zuo, Ning Li, Mingxia Ding, Chong Li
Bladder cancer becomes a serious medical and social concern due to its high recurrence and mortality rates. Thus, it is urgent to search a novel prognostic biomarker and targeted therapy with high sensitivity and specificity. In this study, we used the human bladder cancer cell line EJ as an immunogen to generate a novel mouse monoclonal antibody KMP1 that specifically bound to bladder cancer, and then, the antitumor effect of KMP1 against bladder cancer was investigated both in vivo and in vitro. The results showed that expression of the KMP1 epitope is consistent with clinical severity and prognosis of bladder cancer...
March 25, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29558461/molecular-and-bioinformatics-analyses-identify-7-circular-rnas-involved-in-regulation-of-oncogenic-transformation-and-cell-proliferation-in-human-bladder-cancer
#8
Dawei Cai, Zongjian Liu, Guangqi Kong
BACKGROUND Circular RNAs (circRNAs) have emerged as important regulators in carcinogenesis and metastasis. However, the knowledge of circRNAs in bladder cancer remains limited. This study aimed to investigate the role and mechanism of circRNAs in the development and progression of bladder cancer. MATERIAL AND METHODS Three pairs of bladder carcinomas (including high- and low-grade tumors) and adjacent normal tissues were collected from patients. The total RNAs were extracted from these samples and subjected to Clariom D microarray assays to detect the differentially expressed circRNAs and mRNAs...
March 20, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29542328/waiting-in-the-wings-the-emerging-role-of-molecular-biomarkers-in-bladder-cancer
#9
Dafina Ilijazi, Mohammad Abufaraj, Melanie R Hassler, Iris E Ertl, David D'Andrea, Shahrokh F Shariat
Bladder cancer (BCa) is the fifth most frequently diagnosed cancer worldwide and is, in fact, the most expensive cancer on a per-patient to treat basis. There is a critical need to implement new tests into clinical practice to improve the quality of clinical care, decrease unnecessary invasive therapies and ultimately save costs. Currently, no molecular or genetic biomarker has been widely integrated into daily clinical practice. However, major milestones have been achieved in our understanding of the molecular alterations in BCa that will provide the basis for integrating molecular and genetic biomarkers into clinical decision making to guide management...
March 15, 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/29531584/ki-67-expression-as-a-predictive-factor-of-muscle-invasion-in-bladder-cancer
#10
Syah Mirsya Warli, Dhirajaya Dharma Kadar, Ginanda Putra Siregar
BACKGROUND: Bladder cancer is the 9th most frequent cancer worldwide. Ki-67 is immunohistochemistry marker that is predictive of cancer cell proliferation. The expression of Ki-67 is associated with poor prognosis in several types of malignancy, yet the value of Ki-67 as the prognostic factor in bladder cancer remains controversial. AIM: This study is aimed to investigate the association between Ki-67 expression with muscle-invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NMIBC)...
February 15, 2018: Open Access Macedonian Journal of Medical Sciences
https://www.readbyqxmd.com/read/29530466/circulating-tumor-cells-in-bladder-cancer-emerging-technologies-and-clinical-implications-foreseeing-precision-oncology
#11
REVIEW
Rita Azevedo, Janine Soares, Andreia Peixoto, Sofia Cotton, Luís Lima, Lúcio Lara Santos, José Alexandre Ferreira
CONTEXT: Circulating tumor cells (CTC) in peripheral blood of cancer patients provide an opportunity for real-time liquid biopsies capable of aiding early intervention, therapeutic decision, response to therapy, and prognostication. Nevertheless, the rare and potentially heterogeneous molecular nature of CTC has delayed the standardization of robust high-throughput capture/enrichment and characterization technologies. OBJECTIVE: This review aims to systematize emerging solutions for CTC analysis in bladder cancer (BC), their opportunities and limitations, while providing key insights on specific technologic aspects that may ultimately guide molecular studies and clinical implementation...
March 9, 2018: Urologic Oncology
https://www.readbyqxmd.com/read/29527009/phase-ii-study-of-everolimus-rad001-monotherapy-as-first-line-treatment-in-advanced-biliary-tract-cancer-with-biomarker-exploration-the-radichol-study
#12
David K Lau, Rebecca Y Tay, Yvonne H Yeung, Fiona Chionh, Jennifer Mooi, Carmel Murone, Effie Skrinos, Timothy J Price, John M Mariadason, Niall C Tebbutt
BACKGROUND: Advanced biliary tract cancers (BTCs) have a poor prognosis and limited treatment options. This exploratory phase II study aimed to evaluate the activity of the mTOR inhibitor everolimus in advanced BTC and explore prognostic biomarkers. METHODS: Patients with advanced BTCs, who had not received chemotherapy for advanced disease, were enroled to receive everolimus (10 mg daily). The primary endpoint was disease control rate (DCR) at 12 weeks. Secondary endpoints included overall response rate, progression-free survival (PFS), overall survival (OS) and adverse events...
March 12, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29520382/unmasking-molecular-profiles-of-bladder-cancer
#13
REVIEW
Xuan-Mei Piao, Young Joon Byun, Wun-Jae Kim, Jayoung Kim
Precision medicine is designed to tailor treatments for individual patients by factoring in each person's specific biology and mechanism of disease. This paradigm shifted from a "one size fits all" approach to "personalized and precision care" requires multiple layers of molecular profiling of biomarkers for accurate diagnosis and prediction of treatment responses. Intensive studies are also being performed to understand the complex and dynamic molecular profiles of bladder cancer. These efforts involve looking bladder cancer mechanism at the multiple levels of the genome, epigenome, transcriptome, proteome, lipidome, metabolome etc...
March 2018: Investigative and Clinical Urology
https://www.readbyqxmd.com/read/29517839/pcmt1-is-an-unfavorable-predictor-and-functions-as-an-oncogene-in-bladder-cancer
#14
Liming Dong, Yanpei Li, Dongwei Xue, Yili Liu
The role of protein l-isoaspartate (d-aspartate) O-methyltransferase (PCMT1) in human cancer was generally cognized. The clinical significance and biological function of PCMT1 in bladder cancer is still unknown. PCMT1 mRNA and protein expression levels in bladder cancer tissues and cell lines were detected by qRT-PCR, immunohistochemistry, or western blot. The correlation between PCMT1 expression and clinicopathological factors was analyzed through immunohistochemistry in 108 bladder cancer patients. Loss-of-function and gain-of-function studies were conducted to explore the biological function of PCMT1 in bladder cancer cell lines in regulating cell proliferation, migration, and invasion...
March 8, 2018: IUBMB Life
https://www.readbyqxmd.com/read/29516641/cell-free-lncrna-expression-signatures-in-urine-serve-as-novel-non-invasive-biomarkers-for-diagnosis-and-recurrence-prediction-of-bladder-cancer
#15
Lutao Du, Weili Duan, Xiumei Jiang, Li Zhao, Juan Li, Rui Wang, Suzhen Yan, Yujiao Xie, Keqiang Yan, Qingliang Wang, Lili Wang, Yongmei Yang, Chuanxin Wang
Cell-free long non-coding RNAs (lncRNAs) are stably present in urine and can serve as non-invasive biomarkers for cancer. We aimed to identify signatures of lncRNAs in urine for diagnosis and prognosis of bladder cancer (BC). Screening of lncRNAs by microarray analysis was performed using urine samples of 10 BC patients and 10 controls. Expressions of candidate lncRNAs were evaluated in the training and validation set including 230 BC patients and 230 controls by quantitative reverse transcription polymerase chain reaction (qRT-PCR)...
March 8, 2018: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/29487706/clinical-prognostic-and-therapeutic-significance-of-heat-shock-protein-27-in-bladder-cancer
#16
Myung-Shin Lee, Jisu Lee, Suhyuk Lee, Seung-Min Yoo, Joo Heon Kim, Won Tae Kim, Wun-Jae Kim, Jinsung Park
Heat shock protein 27 (HSP27) is highly expressed in many cancers, and its prognostic and predictive value has been reported. HSP27 knockdown using siRNA or OGX-427 (an anti-sense oligonucleotide sequence targeting HSP27) is reported to have anti-cancer effects and to enhance chemosensitivity of cancer cells to chemotherapeutic agents. However, conflicting results have been reported regarding the clinical significance of HSP27 in bladder cancer (BC). Furthermore, long-term suppression of HSP27 has not been investigated in BC...
January 30, 2018: Oncotarget
https://www.readbyqxmd.com/read/29475387/choline-phosphate-cytidylyltransferase-%C3%AE-as-a-possible-predictor-of-survival-and-response-to-cisplatin-neoadjuvant-chemotherapy-in-urothelial-cancer-of-the-bladder
#17
Tammer Hemdan, Polat Turker, Per-Uno Malmström, Ulrika Segersten
OBJECTIVES: The aim of this study was to test choline-phosphate cytidylyltransferase-α (CCT-α) protein as a biomarker for neoadjuvant cisplatin chemotherapy response in a bladder tumor setting. MATERIALS AND METHODS: A total of 238 patients with T2-T4 bladder cancer enrolled into two prior randomized trials comparing neoadjuvant cisplatin-based chemotherapy (NAC) plus cystectomy with cystectomy only (no-NAC) were used as discovery and validation cohorts. Protein expression was determined with immunohistochemistry and assessed with Histo (H)-scoring...
February 23, 2018: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/29455872/-pd-l1-expression-and-pd-1-pd-l1-inhibitors-in-breast-cancer
#18
REVIEW
Audrey Monneur, Anthony Gonçalves, François Bertucci
The development of immune checkpoints inhibitors represents one of the major recent advances in oncology. Monoclonal antibodies directed against the programmed cell death protein 1 (PD-1) or its ligand (PD-L1) provides durable disease control, particularly in melanoma, lung, kidney, bladder and head and neck cancers. The purpose of this review is to synthesize current data on the expression of PD-L1 in breast cancer and on the preliminary clinical results of PD-1/PD-L1 inhibitors in breast cancer patients. In breast cancer, PD-L1 expression is heterogeneous and is generally associated with the presence of tumor-infiltrating lymphocytes as well as the presence of poor-prognosis factors, such as young age, high grade, ER-negativity, PR-negativity, and HER-2 overexpression, high proliferative index, and aggressive molecular subtypes (triple negative, basal-like, HER-2-overexpressing)...
February 15, 2018: Bulletin du Cancer
https://www.readbyqxmd.com/read/29438779/down-regulation-of-mirna-320c-promotes-tumor-growth-and-metastasis-and-predicts-poor-prognosis-in-human-glioma
#19
Qiao-Li Lv, Hui-Ting Zhu, Xiao-Hua Cheng, Hong-Mi Li, Hong-Hao Zhou, Shu-Hui Chen
Emerging studies show that dysregulated miRNAs are implicated in tumorigenesis and progression of various cancers. MiRNA-320c, an important member of miRNA-320 family, was characterized as a new candidate miRNA that suppressed the development of colorectal cancer and bladder cancer. However, the function of miRNA-320c in human glioma remained unclear. Here, we found that miRNA-320c was significantly down-regulated in glioma tissues and cell lines in contrast with normal brain tissues, being tightly related to clinical stage of glioma by qRT-PCR...
February 10, 2018: Brain Research Bulletin
https://www.readbyqxmd.com/read/29426697/the-prognostic-value-of-basal-dna-damage-level-in-peripheral-blood-lymphocytes-of-patients-affected-by-bladder-cancer
#20
Alessandra Allione, Barbara Pardini, Clara Viberti, Marco Oderda, Marco Allasia, Paolo Gontero, Paolo Vineis, Carlotta Sacerdote, Giuseppe Matullo
BACKGROUND: Bladder cancer (BC) is one of the most aggressive malignancies of the urinary tract, with the highest lifetime treatment costs per patient of all cancers, due to the high rate of recurrences requiring continuous surveillance. An early diagnosis is essential to improve survival of patients with BC. Noninvasive and sensitive molecular biomarkers are needed to improve current strategies for the detection and monitoring of BC. Previous studies suggested that elevated DNA damage levels and suboptimal nucleotide excision DNA repair (NER) may be associated with BC...
February 6, 2018: Urologic Oncology
keyword
keyword
73141
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"